Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...
Medscape1h
Pathologic Complete Response Shows Poor Surrogacy for OS in Breast Cancer Trials
Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...
GlaxoSmithKline (GSK) Gets a Hold from UBS
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...
Glaxosmithkline Pharmaceuticals Ltd leads gainers in 'A' group
Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmalabs Ltd are among the other gainers in the BSE's 'A' group today, 06 February 2025.
CFRA cuts GlaxoSmithKline stock price target to $40, maintains hold
CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...
Daily Record (Morristown, NJ) on MSN3h
Parsippany demolished 2 million square feet of office space. Here's what will replace it
While the controversy − and legal battles − heat up over New Jersey's affordable housing mandate, an explosion of ...
American Association of Individual Investors13h
Which Is a Better Investment, Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. Stock?
Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...
Analgesics Market Expected To Reach USD 131.29 Billion by 2032,Growing at CAGR of 4.6% | Johnson & Johnson, Pfizer Inc., GlaxoSmithKline
Exploring Analgesics as a Key Painkiller Types & Their Role in Pain ReliefUnited States, New York, Feb. 04, 2025 (GLOBE ...
American Association of Individual Investors21h
Which Is a Better Investment, Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. Stock?
Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...
PharmiWeb7h
BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36…
IPOBIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025 06.02.2025 / 07:00 CET/CEST__________THIS IS A RESTRICTED ...
Dynavax Technologies: Time To Refocus On Former Cash Cow CpG1018
Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...
EurekAlert!1d
Using genetics to identify individuals with undiagnosed chronic obstructive pulmonary disease (COPD)
In a recent study, Mass General Brigham researchers demonstrated that through low-cost genetic samples, that can be obtained from a cheek swab or blood test, they can improve identification of people ...